HUP0402619A3 - Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure - Google Patents

Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure

Info

Publication number
HUP0402619A3
HUP0402619A3 HU0402619A HUP0402619A HUP0402619A3 HU P0402619 A3 HUP0402619 A3 HU P0402619A3 HU 0402619 A HU0402619 A HU 0402619A HU P0402619 A HUP0402619 A HU P0402619A HU P0402619 A3 HUP0402619 A3 HU P0402619A3
Authority
HU
Hungary
Prior art keywords
medicament
preparation
treatment
reuptake inhibitors
norepinephrine reuptake
Prior art date
Application number
HU0402619A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0402619A2 publication Critical patent/HUP0402619A2/hu
Publication of HUP0402619A3 publication Critical patent/HUP0402619A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0402619A 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure HUP0402619A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (2)

Publication Number Publication Date
HUP0402619A2 HUP0402619A2 (hu) 2005-03-29
HUP0402619A3 true HUP0402619A3 (en) 2008-04-28

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402619A HUP0402619A3 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure

Country Status (26)

Country Link
US (1) US20050009925A1 (https=)
EP (1) EP1458368B1 (https=)
JP (1) JP2005517647A (https=)
KR (1) KR20040066895A (https=)
CN (1) CN1713900A (https=)
AU (1) AU2002352625A1 (https=)
BR (1) BR0213581A (https=)
CA (1) CA2467802A1 (https=)
CO (1) CO5590907A2 (https=)
CZ (1) CZ2004709A3 (https=)
DE (1) DE60223718T2 (https=)
EA (1) EA200400793A1 (https=)
EC (1) ECSP045145A (https=)
ES (1) ES2295435T3 (https=)
HR (1) HRPK20040528B3 (https=)
HU (1) HUP0402619A3 (https=)
IL (1) IL161989A0 (https=)
MX (1) MXPA04005716A (https=)
MY (1) MY136367A (https=)
NO (1) NO20042904L (https=)
NZ (1) NZ532065A (https=)
PL (1) PL369311A1 (https=)
SK (1) SK2442004A3 (https=)
TW (1) TW200300672A (https=)
WO (1) WO2003049724A1 (https=)
ZA (1) ZA200404274B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
EP1729754B1 (en) * 2003-12-12 2008-07-02 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
WO2011014475A2 (en) * 2009-07-31 2011-02-03 National Taiwan University Treating negative symptoms of schizophrenia associated with defective neuregulin 1
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
AP2002002481A0 (en) * 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
BR0213581A (pt) 2004-08-24
CA2467802A1 (en) 2003-06-19
DE60223718D1 (de) 2008-01-03
US20050009925A1 (en) 2005-01-13
ECSP045145A (es) 2004-07-23
KR20040066895A (ko) 2004-07-27
DE60223718T2 (de) 2008-10-30
ZA200404274B (en) 2005-09-13
HRPK20040528B3 (en) 2006-03-31
CZ2004709A3 (cs) 2004-10-13
AU2002352625A1 (en) 2003-06-23
EP1458368A1 (en) 2004-09-22
HUP0402619A2 (hu) 2005-03-29
TW200300672A (en) 2003-06-16
JP2005517647A (ja) 2005-06-16
SK2442004A3 (en) 2004-12-01
MXPA04005716A (es) 2004-12-06
CO5590907A2 (es) 2005-12-30
WO2003049724A1 (en) 2003-06-19
NO20042904L (no) 2004-09-07
EP1458368B1 (en) 2007-11-21
ES2295435T3 (es) 2008-04-16
EA200400793A1 (ru) 2004-10-28
NZ532065A (en) 2007-03-30
HRP20040528A2 (en) 2004-10-31
IL161989A0 (en) 2005-11-20
CN1713900A (zh) 2005-12-28
PL369311A1 (en) 2005-04-18
MY136367A (en) 2008-09-30

Similar Documents

Publication Publication Date Title
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0301887A3 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
PL370818A1 (en) Dosage form for treatment of diabetes mellitus
IL158590A0 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
HUP0402619A3 (en) Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure
IL173145A (en) Use of a pak inhibitor for the production of a medicament for the treatment of a joint disease
HUP0400222A3 (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
ZA200403568B (en) Treatment of a wide range of titanium compounds.
IL167187A (en) Composition comprising modafinil, said composition for use as a medicament and use of said composition for the preparation of medicament
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
PL375629A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
IL150290A (en) Use of mirtazapine for preparation of a medicament for the treatment of sleep disorders
PT1534296E (pt) UTILIZAÇÃO DE CILOBRADINA OU DOS SEUS SAIS FARMACEUTICAMENTE ACEITÁVEIS PARA O TRATAMENTO OU PREVENÇÃO DA INSUFICIjNCIA CARDÍACA
WO2002083083A3 (en) Pharmaceutically active compounds and methods of use
IL162509A (en) Use of deoxypeganine for the production of a drug for treating clinical depression
IL155431A0 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
HK1069540A (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
GB0212790D0 (en) Medicament for the treatment of diabetes
SI1458376T1 (sl) Darifenacin za uporabo pri zdravljenju nuje, ki je posledica prekomerno aktivnega sečnega mehurja
MXPA03010919A (es) Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor.
PL367634A1 (en) Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
IL162125A (en) Use of n-(indolcarbonyl)- piperazine derivatives for the preparation of medicaments for the treatment of obesity

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees